Skip to content
The Morning Dispatch: Is Vaccine Tech Too Precious to Patent?
Go to my account

The Morning Dispatch: Is Vaccine Tech Too Precious to Patent?

Plus: Ongoing unrest in Burma, and a look at Liz Cheney's likely successor in House leadership.

Happy Friday! We hope we are not the first to remind you that Mother’s Day is this Sunday. Order those flowers! Mail that card! Make those brunch reservations! Buy that gift membership to The Dispatch! 

Quick Hits: Today’s Top Stories

  • Florida Gov. Ron DeSantis signed into law on Thursday a package of election reforms passed by the state legislature last week with only Republican support. The bill, S.B. 90, will require Floridians to reapply for absentee ballots every year and limits ballot drop boxes to election supervisors’ offices or early-voting sites, among other provisions.

  • South Carolina Gov. Henry McMaster on Thursday ordered the state’s Department of Employment and Workforce to cease participation in federal and pandemic-related unemployment benefit programs, effective June 30. McMaster said employers in the state face an “unprecedented labor shortage,” which he attributed in large part to the $300-per-week federal unemployment insurance boost.

  • Initial jobless claims decreased by 92,000 week-over-week to 498,000 last week, the Labor Department reported on Thursday, the lowest level since March 14, 2020.

  • The United States confirmed 46,644 new cases of COVID-19 yesterday per the Johns Hopkins University COVID-19 Dashboard, with 3.0 percent of the 1,566,493 tests reported coming back positive. An additional 789 deaths were attributed to the virus on Thursday, bringing the pandemic’s American death toll to 580,054. According to the Centers for Disease Control, 33,808 Americans are currently hospitalized with COVID-19. Meanwhile, 2,406,932 COVID-19 vaccine doses were administered yesterday, with 149,462,265 Americans having now received at least one dose.

A Worldwide Fight Over COVID IP

As COVID cases fester around the world, particularly hard-hit nations desperate for more vaccines have spent recent months lobbying the World Trade Organization (WTO) with a remarkable argument: COVID vaccines and treatments are too important to remain in the hands of a few private companies. The WTO, they say, should waive the manufacturers’ intellectual property rights in the hope of juicing production in the developing world.

The Trump White House had staunchly opposed the proposal, which India and South Africa first brought to the WTO in November. On Wednesday, however, the Biden administration—amid reports of out-of-control spread in India and under pressure from congressional Democrats—threw its weight behind the effort. “This is a global health crisis,” U.S. trade representative Katherine Tai said in a statement, “and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures.”

The waiver still isn’t a sure thing: Such actions need to be unanimous among WTO member countries, and the EU has continued to drag its heels. German chancellor Angela Merkel said Thursday she remains opposed to the waiver, which she said would not improve vaccine availability. “The protection of intellectual property is a source of innovation,” she said, “and it must remain so in the future.” BioNTech, which worked with Pfizer to develop its vaccine, is headquartered in Mainz, Germany. 

Congressional Republicans and the pharmaceutical industry sounded similar notes. GOP Rep. Byron Donalds, who is introducing legislation that would block Biden from authorizing the plan, called it “a direct infringement upon American ingenuity and innovation” that would “hand over our nation’s intellectual prowess for the world’s taking” in a Thursday appearance on Fox News. Steve Ubl, head of the industry trade group Pharmaceutical Research and Manufacturers of America, said the waiver would mean “handing over American innovations to countries looking to undermine our leadership in biomedical discovery.”  

It’s worth noting that the vaccines in question benefitted from a good deal of federal help—as is often the case with vaccine development, given the public-health benefits of eradicating disease and the relatively low profitability of vaccines in general. During the Trump administration, Operation Warp Speed disbursed more than $12 billion to accelerate vaccine manufacturing, funding vaccine research with eight different companies and distribution at others (including Pfizer, which funded its own research) by means of large advance contracts.

If it were certain, then, that waiving vaccine patents would in fact put rocket boosters on global vaccine production and availability, you could see why Team Biden would be comfortable waving off market concerns in a display of global U.S. leadership. But this remains far from clear. It’s one thing to tell other companies in other countries they’re permitted to copy, for example, Pfizer or Moderna’s mRNA technology; it’s another thing for them to actually put that in practice. 

“We are at risk for this disease as long as other countries are at risk for this disease, so it’s in our interest to make sure that as many groups can manufacture this by whatever means,” Dr. Paul Offit, a virologist at the Children’s Hospital of Philadelphia, told The Dispatch. “The only caveat is, as the old saying goes, the hardest part of making vaccines is making vaccines.”

Opening up manufacturing of a complex biological like a vaccine, Offit said, is far different from producing other sorts of simpler generic drugs.

“When you license a small-molecule drug like amoxicillin, it’s not that hard—you just need to make sure that there’s 50 milligrams per tablet in this batch, 50 milligrams per tablet in that batch, because it’s easy to characterize small molecules,” Offit said. “It’s not as easy to characterize biologicals. So the process becomes the product, and it’s the process that really gets licensed more than anything else.”

Getting other companies to produce COVID vaccines, in other words, will require a lot more than waiving a patent. New factories would need to be built, new supply chains developed, and new high-skilled workforces trained—all in large part through the efforts of the companies whose efforts brought us the vaccines in the first place and who would undoubtedly be getting the short end of the stick on this deal.

“There’s a reason China has not yet produced an mRNA vaccine—because they can’t,” Alex Tabarrok, an expert in financial economics and professor of economics at George Mason University, told The Dispatch. “There’s not a bunch of factories in China where you could just call them up and say, ‘Here’s the chip, and can you make this for me?’ And they’d say, ‘Yes, sir, we’ll have it for you in 48 hours.’ These factories have never been built before.”

When it comes to global vaccine availability, Tabarrok argues that the patent discussion is, in essence, a red herring. The current bottlenecks that exist aren’t artificial barriers of permission to manufacture; they’re concrete cases of difficulty meeting demand at various points in the vaccines’ complex global supply chains.

Given these facts, it’s fair to look at Biden’s abrupt change of direction as a messaging move—one aimed at shoring up his position both among U.S. progressives and other nations’ leaders. Sens. Elizabeth Warren and Bernie Sanders heaped praise on the move Thursday, with Sanders calling it “a bold step in response to the world’s most urgent crisis” and an act of “putting people over profits.”

This also might help to explain why Biden didn’t opt for a different route toward increasing vaccine availability. Rather than compelling Pfizer and Moderna to give up trade secrets to anyone who might want to make use of them, he might have simply handed the companies another pile of money to use on getting even more doses out as quickly as possible. After all, they’re the ones who already have months of experience squeezing every drop of production they can out of their own supply chains. As things stand, they have little financial reason to continue to scale up their operations significantly beyond the doses they’re already contracted for—especially given that demand for mRNA vaccines isn’t likely to be anywhere near as high in, say, 2025 as it is today.

“We want speed, but speed may mean building a factory which is going to be obsolete, we hope, very soon,” Tabarrok said. “So if you want to incentivize a firm to build a factory which is going to be obsolete in six months, then you have to pay.”

That, however, would likely be a nonstarter for Biden politically—at least among the Sanders/Warren crowd.

The Latest in Burma

#WhatsHappeningInMyanmar is once again trending on Twitter, as opponents of Burma’s February 1 military coup share videos and images of state-perpetrated violence in an effort to project their plight worldwide. After 95 days under the illegitimate junta leadership—which has adopted methods including arbitrary detainment, torture, and extrajudicial execution to regain control of the country—protests persist with no signs of letting up. 

https://twitter.com/MOESI15109958/status/1390466700995223552

According to the Assistance Association for Political Prisoners—an independent group monitoring the situation in Burma post-military takeover—more than 3,700 people have been arrested, charged, or sentenced in connection to the protests. As of Thursday night, per the same organization, at least 770 people—including a nine-year-old child—have been killed by security forces during the crackdowns.

Despite widespread international outrage in response to the violence, the generals haven’t been shy about their methods. Myawaddy TV—Burma’s military-owned network—broadcasts nightly coverage of the demonstrations, featuring footage of bruised and bloodied protesters to deter others from taking to the streets. The junta announced a ban on satellite television Tuesday, restricting civilian access to independent Burmese language broadcasters credited with fostering dissent, like Mizzima and the Democratic Voice of Burma. 

Other military tactics—like deploying plainclothes officers to seize civilians, cutting off mobile data, and opening fire without provocation—are also intended to quell regular gatherings. 

In a report Wednesday, Associated Press detailed extensive evidence that security forces may be kidnapping young men and boys to put down the uprising. Civilians disappearing across the country are disproportionately male, and being held in undisclosed locations.

“The Burmese army has a long history of forced conscription, including of children. So do some of the ethnic armed organizations that it is fighting. Undoing that state of affairs was a major focus over the last decade which had seen significant progress,” Gregory B. Poling, a senior fellow for Southeast Asia at the Center for Strategic and International Studies, told The Dispatch. “It would be a tragedy, though not entirely surprising, if that progress is another victim of the current crisis.”

Meanwhile, opposition forces—led by Aung San Suu Kyi’s government in exile—have begun taking steps to form an army of their own. The group introduced the “people’s defense force” Wednesday as a way to protect civilians from the junta. In theory, people loyal to the deposed government would work in union with ethnic fighters across the country to oppose the existing leadership.

But this might be easier said than done. The diverse and dispersed ethnic militias harbor suspicion toward the civilian government, particularly given its complacency in the military’s crimes against Burma’s Muslim Rohingya minority.

On Sunday, the UN Security Council released another condemnation in a string of statements since February. “The Members of the Security Council reiterated their deep concern at the situation in Myanmar following the declaration of the state of emergency imposed by the military on 1 February, and reiterated their support for Myanmar’s democratic transition,” the group wrote. “They called once again for the release of all those arbitrarily detained, including State Counsellor Aung San Suu Kyi and President Win Mint.”

But as military crackdowns intensify in force and frequency, human rights organizations are pushing for more tangible steps. 200 plus advocacy groups, including Amnesty International and Human Rights Watch, have joined together to call on the UN to impose an arms embargo on Burma. 

“No government should sell a single bullet to the junta under these circumstances. Imposing a global arms embargo on Myanmar is the minimum necessary step the Security Council should take in response to the military’s escalating violence,” said the joint statement. “Arms and materiel provided to Myanmar’s security forces are likely to be used by the security forces to commit abuses in violation of international human rights and humanitarian law.”

“Mere condemnation by the international community has had no effect,” Lawrence Moss, Amnesty International’s Senior UN Advocate, said Wednesday. “It is time for the UN Security Council to use its unique powers to impose a comprehensive global arms embargo in order to try and end the military’s killing spree.”

Meet the New Boss

A couple days back, we covered the intra-party battle that is taking place within the House Republican conference, which will likely lead to Rep. Liz Cheney’s ouster from leadership next week.

In an excellent edition of Uphill today, Haley goes deep on Rep. Elise Stefanik, the 36-year-old from upstate New York widely expected to take Cheney’s place. Former President Trump endorsed Stefanik for the role earlier this week, which will all but surely give her the support she needs among Republicans—despite her relatively moderate voting record.

Who is Stefanik, and how did she get here?

Stefanik was formerly a White House policy adviser in George W. Bush’s administration. She represents New York’s rural 21st Congressional District, which she won by more than 22 points when she was first elected in 2014. She held the record as the youngest woman ever elected to Congress for several years, until Rep. Alexandria Ocasio-Cortez won her race in 2018 at the age of 29.

Stefanik was once known primarily for her more moderate policy views and her efforts to encourage more GOP women to run for office. But she rose to MAGA stardom during Trump’s first impeachment inquiry, when she emerged as one of his most outspoken defenders. Her seat on the House intelligence panel gave her a high-profile role during the hearings, setting up clashes with committee chair Adam Schiff. The spotlight also enabled her to raise millions of dollars from Trump fans who were following the proceedings.

What has she been saying this week?

In an interview with former Trump adviser Steve Bannon on Thursday, Stefanik continued to raise questions about the 2020 presidential election, throwing her approval behind the Republican-led Maricopa County recount, which now includes an investigation into whether there are bamboo fibers in the ballots after unfounded claims that 40,000 ballots were flown in from Asia to help stuff ballot boxes. (Yes, we’re serious.) 

She also outlined how she will approach the GOP conference chair position if elected—presenting a vision starkly different than Cheney’s. “My vision is to run with support from the president and his coalition of voters, which was the highest number of votes ever won by a Republican nominee in 2020,” she said, referring to Trump.

“This is also about being one team,” Stefanik added. “And I’m committed to being a voice and sending a clear message that we are one team, and that means working with the president and working with all of our excellent Republican members of Congress.” (For clarity, her use of “the president” in this instance is again referring to Trump.)

Worth Your Time

  • In a comprehensive piece on Medium, longtime science journalist Nicholas Wade digs into what we know—and what we still don’t—about the late 2019 genesis of SARS-CoV-2 in Wuhan. “There are two main theories about its origin. One is that it jumped naturally from wildlife to people. The other is that the virus was under study in a lab, from which it escaped. It matters a great deal which is the case if we hope to prevent a second such occurrence,” he writes, noting there is “no direct evidence” for either theory, but that most of the clues point toward a lab leak. “It’s documented that researchers at the Wuhan Institute of Virology were doing gain-of-function experiments designed to make coronaviruses infect human cells and humanized mice. This is exactly the kind of experiment from which a SARS2-like virus could have emerged. The researchers were not vaccinated against the viruses under study, and they were working in the minimal safety conditions of a BSL2 laboratory. So escape of a virus would not be at all surprising. In all of China, the pandemic broke out on the doorstep of the Wuhan institute.”

Presented Without Comment

Also Presented Without Comment

Toeing the Company Line

  • Has the election audit in Maricopa County yielded hundreds of thousands of votes? No, finds Khaya Himmelman’s latest Dispatch Fact Check. “At this time no evidence of voter fraud has been reported in Maricopa County from this audit. The official Arizona audit website has not released any information regarding the results.”

  • Chris Stirewalt is back on The Remnant this week, talking to Jonah about MAGA v. Liz Cheney, and President Biden supposedly ushering in a New Progressive Era.

  • David’s wife got a flat tire yesterday and needed a tow, so Sarah rode solo on Thursday’s episode of Advisory Opinions—at least until she was joined by Jonathan Ellis, an assistant to the solicitor general of the United States. Tune in to hear Jonathan chat about what it’s like representing the U.S. government in front of the Supreme Court, how many cases he argues per term, and more.

  • In this week’s Vital Interests (🔒), Thomas Joscelyn digs into how the Chinese government responded to President Biden’s address to Congress last week. “Obviously, the CCP has no interest in promoting real democracy,” he notes. “The CCP monopolizes China’s politics as an autocracy. What [China’s foreign ministry spokesman Wang Wenbin] was really getting at is that the CCP doesn’t want the U.S. or other Western countries to promote their form of democracy first and foremost inside China, but also likely elsewhere.”

Let Us Know

In honor of Mother’s Day this weekend, let us know one of your favorite memories you have of you and your mom. If you could only tell one story to explain her, what would it be?

Reporting by Declan Garvey (@declanpgarvey), Andrew Egger (@EggerDC), Haley Byrd Wilt (@byrdinator), Audrey Fahlberg (@FahlOutBerg), Charlotte Lawson (@charlotteUVA), Ryan Brown (@RyanP_Brown), and Steve Hayes (@stephenfhayes).

Please note that we at The Dispatch hold ourselves, our work, and our commenters to a higher standard than other places on the internet. We welcome comments that foster genuine debate or discussion—including comments critical of us or our work—but responses that include ad hominem attacks on fellow Dispatch members or are intended to stoke fear and anger may be moderated.

You are currently using a limited time guest pass and do not have access to commenting. Consider subscribing to join the conversation.